Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0003613090

MOBERG PHARMA AB (PUBL) (MOB)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Moberg Pharma publ : NOMINATION COMMITTEE APPOINTED

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:31am CEST

STOCKHOLM, November 10th, 2017 - In accordance with the resolution of the Annual General Meeting on May 18, 2017, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company's three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18.

Moberg Pharma's Nomination Committee ahead of the 2018 Annual General Meeting comprises: 

·  Thomas Eklund, Chairman of the Board
·  Gillis Cullin, appointed by Östersjöstiftelsen
·  Fredrik Persson, appointed by Zimbrine Holding
·  Anders Rodebjer, appointed by Wolco Invest

Together, the Nomination Committee represents 25.3 percent of the shares in Moberg Pharma as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2018 Annual General Meeting will be held in Stockholm on May 15.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to info@mobergpharma.se by 31 December 2017.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on November 10th, 2017

For additional information, please contact:
Peter Wolpert, CEO, Phone: +1 908 432 22 03 (US), +46 707 35 71 35 (SE), E-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

http://news.cision.com/moberg-pharma/r/moberg-pharma-s-nomination-committee-appointed,c2387146

http://mb.cision.com/Main/1662/2387146/749074.pdf

(c) 2017 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MOBERG PHARMA AB (PUBL)
09/20CIPHER PHARMACEUTICALS : Acquires Exclusive Canadian Rights to MOB-015 from Mobe..
AQ
09/18MOBERG PHARMA PUBL : and Cipher Pharmaceuticals sign exclusive license agreement..
AQ
09/11MOBERG PHARMA PUBL : has completed enrollment to Phase 3 study for MOB-015 in No..
AQ
08/13MOBERG PHARMA PUBL : Appointment of Chief Medical Officer at Moberg Pharma
AQ
08/07MOBERG PHARMA AB : interim report January - June 2018
AQ
07/30MOBERG PHARMA PUBL : report for the second quarter to be published on August 7 -..
PU
07/30MOBERG PHARMA PUBL : report for the second quarter to be published on August 7 -..
AQ
06/29MOBERG PHARMA PUBL : New number of shares and votes in Moberg Pharma AB (publ)
AQ
06/20MOBERG PHARMA PUBL : Addition to Moberg Pharma’s management team
PU
06/20MOBERG PHARMA PUBL : Addition to Moberg Pharma's management team
AQ
More news
News from SeekingAlpha
05/08Moberg Derma AB reports Q1 results 
02/13Moberg Derma AB reports Q4 results 
2017Moberg Pharma (MBGRF) Presents At Pareto Securities' 8th Annual Health Care S.. 
Financials (SEK)
Sales 2018 432 M
EBIT 2018 56,0 M
Net income 2018 10,2 M
Debt 2018 481 M
Yield 2018 -
P/E ratio 2018 71,67
P/E ratio 2019 61,63
EV / Sales 2018 3,28x
EV / Sales 2019 3,09x
Capitalization 935 M
Chart MOBERG PHARMA AB (PUBL)
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Peter Gunnar Maurits Wolpert Chief Executive Officer
Thomas Lennart Eklund Chairman
Anna Ljung Chief Financial Officer
Shaw Sorooshian Chief Medical Officer & Vice President
Geert Cauwenbergh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MOBERG PHARMA AB (PUBL)90.61%104
JOHNSON & JOHNSON-4.19%359 060
PFIZER20.87%250 957
NOVARTIS-0.49%211 413
ROCHE HOLDING LTD.-4.44%204 875
MERCK AND COMPANY24.06%181 832